 OMA wins Communicator Award
On April 26, OMA received the Communicator Awards' Silver Award of Distinction in the category of brand launch and corporate identity campaigns. The Communicator Awards is the leading international awards program honoring creative excellence for communication professionals. More than 6,000 entries were submitted in 2016 and judged by members of the Academy of Interactive and Visual Arts, which consists of acclaimed media, advertising, and marketing firms. We thank you for your support of the new brand and throughout the rebranding process -- we would not have won this award without you! |
 |
 Apply to join the Board of Trustees
Take your leadership to the next level and become more involved! We're now accepting applications for the 2016-2017 Board of Trustees. Interested candidates must complete an application and submit it to OMA via email, fax, or mail by May 16. The following positions are available:
- Vice president (one-year term)
- Secretary/treasurer (one-year term)
- Trustee (three positions available, each a two-year term)
|
ABOM update: Progress made in 2016
In a letter from Dr. Louis Aronne, the American Board of Obesity Medicine (ABOM) updated the obesity medicine community on what the organization has been up to so far this year.
- Item writing committee: ABOM's item writing committee now has more than 40 participants. The committee is responsible for contributing questions to the test bank for the obesity medicine certification exam.
- Certification management system: The new certification portal streamlines the application process for new candidates and serves as a "home base" for current diplomates to manage their recertification process. Diplomates can even order diplomas on the portal.
- Website: ABOM has a new website! If you haven't seen it yet, check it out at abom.org.
ABOM's progress shows growth in the field of obesity medicine. By continuing to work with ABOM to educate and certify obesity medicine physicians, we can grow the number of members who are diplomates (currently at 50 percent) and make an even bigger impact on the health of patients affected by obesity.
|
|
Obesity Treatment Foundation
|
 Two weeks left to submit your letter of intent for a $15,000 research grant
The Obesity Treatment Foundation (OTF) will offer one research grant this year in the amount of $15,000. This grant will assist an obesity medicine specialist in engaging in clinical research focused on determining effective obesity treatment approaches. OTF is now accepting letters of intent from clinicians interested in applying for this grant. Letters of intent are due by May 13, and selected applicants will be invited to submit full proposals by June 6. Carefully review the submission instructions before submitting your letter of intent. Questions? Contact OTF at stacy@obesitytreatmentfoundation.org.
|
|
Re-evaluation of the traditional diet-heart hypothesis: Analysis of recovered data from Minnesota Coronary Experiment (1968-1973)
Ramsden, C. E., et al. BMJ, 2016.
The Minnesota Coronary Experiment (MCE) was a double-blind randomized controlled trial conducted from 1968-1973 to test whether replacement of saturated fat (from animal fats, common margarines, and shortenings) with linoleic acid (from vegetable oil) reduces coronary heart disease and death by lowering serum cholesterol. The study was conducted in one nursing home and six state mental hospitals in Minnesota. This re-evaluation of the MCE analyzed previously unpublished data from MCE. The analysis found that the linoleic acid group had significant reduction in serum cholesterol compared with controls (-13.8% versus -1.0%); however, there was no mortality benefit for the linoleic acid group in the full randomized cohort or for any subgroup analysis. In fact, there was a 22% higher risk of death for each 30 mg/dL reduction in serum cholesterol. There was no evidence of benefit in the linoleic acid group for coronary atherosclerosis or myocardial infarcts. The authors suggest that incomplete publication of the MCE contributed to the overestimation of the benefits of replacing saturated fat with vegetable oils in regards to risk of death from coronary heart disease. View article
|
|
|
|
Executive Director
Sponsorships and Exhibits Manager
Operations Manager
Education Coordinator
Communication Manager
Executive Director of the Obesity Treatment Foundation
|
|
101 University Blvd.,
Suite 330
Denver, CO 80206
|
|
|
GLP-1 receptors exist in the parietal cortex, hypothalamus, and medulla of human brains, and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial
Farr, O. M., et al. Diabetologia, 2016.
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, is known to improve diabetes and promote weight loss. However, the mechanisms of the weight loss are not fully elucidated. This study investigates whether GLP-1 receptors are expressed in human brains and whether liraglutide administration affects neural responses to food cues in individuals with diabetes. In a randomized, placebo-controlled, double-blind, crossover trial, 21 individuals with type 2 diabetes were given placebo and liraglutide for a total of 17 days each (0.6 mg for 7 days, 1.2 mg for 7 days, and 1.8 mg for 3 days). Results showed that GLP-1 receptors were present on neurons in the human hypothalamus, medulla, and parietal cortex. Liraglutide decreased activation of the parietal cortex in response to highly desirable (versus less desirable) food images. Increased ratings of hunger and appetite correlated with increased brain activation in response to highly desirable food cues. This study suggests that GLP-1 receptors are present in the brain, and liraglutide alters brain activity, which may partially explain the weight loss seen with liraglutide. View article
|
A randomized trial of high-dairy-protein, variable-carbohydrate diets and exercise on body composition in adults with obesity
Parr, E. B., et al. Obesity, 2016.
Dietary advice for individuals with obesity is a hotly debated topic. Interventions that improve body composition -- not just body weight -- are ideal. This study aimed to determine the effects of 16-week high-dairy-protein, variable-carbohydrate (CHO) diets and exercise training (EXT) on body composition in men and women with overweight or obesity. Participants consumed either: high dairy protein, moderate CHO (40% CHO; 30% protein; 30% fat; ∼4 dairy servings); high dairy protein, high CHO (55% CHO; 30% protein; 15% fat; ∼4 dairy servings); or control (55% CHO; 15% protein; 30% fat; ∼1 dairy serving). Energy deficit of 500 kcal/day was achieved through diet ( ∼250 kcal/day) and EXT ( ∼250 kcal/day). Results showed that participants lost 7.7 kg fat mass and gained 0.50 kg lean mass, with no difference in the changes in body composition (fat mass or lean mass) between groups. These findings suggest that energy-restricted high-protein diets containing the proportions of fat and CHO studied provide no advantage to weight loss or change in body composition in the presence of an exercise stimulus. View article
|
|
Featured Presentation on the Obesity Medicine Academy
Food Addiction and ObesityVisit the Obesity Medicine Academy to purchase and watch this presentation about diagnosing and treating food addiction in patients with obesity, presented by Dr. Mark Gold. After you watch the presentation online, pass the quiz to claim 0.75 hours of CME/CE credit. |
Overcoming Obesity 2016
If we missed you in San Francisco, we hope to see you in Chicago this fall! Overcoming Obesity 2016 is your primary source for clinical obesity education. This fall we're offering the Review Course for the ABOM Exam -- the course preferred by physicians to help them prepare for the obesity medicine certification exam -- and the Fall Obesity Summit, which contains an all-new lineup of topics and speakers. Overcoming Obesity 2016 takes place in Chicago on Sept. 21-25. Register online now! |
Review Course for the ABOM Exam
13 CME/CE | Sept. 21-22
Helps prepare those planning to take the American Board of Obesity Medicine (ABOM) certification exam.
| Fall Obesity Summit
17 CME/CE | Sept. 23-25
Addresses topics related to the clinical treatment of obesity and obesity-related conditions.
|
|
Obesity Medicine Basics
Obesity Medicine Basics returns this summer to four cities around the country. This introductory-level course is an opportunity for us to spread the word about obesity medicine to providers in a primary care setting. As a member of OMA, you can earn rewards by referring others to attend Obesity Medicine Basics. Your efforts referring your colleagues to this course will help grow the field of obesity medicine and increase the number of health care professionals with a basic understanding of how to treat obesity. Upcoming Courses: |
|
|
|
The Obesity Medicine Association and the Obesity Treatment Foundation thank our 2016 Corporate Advisory Council members for their continuous support.
|
© 2016 Obesity Medicine Association. All rights reserved. Materials may not be reproduced, redistributed or translated without written permission. Advertising disclaimer: Under a policy approved by the OMA executive committee and exhibitor/advertiser review committee, commercial companies may apply to advertise in OMA publications. Approval does not imply endorsement or official recognition of particular products or services.
|
|
|
|
